Evidence map›Paper›PMID 32029930›Full record

ArticleProstate cancer and prostatic diseases2020

Associations among statins, preventive care, and prostate cancer mortality.

Abhishek Kumar, Paul Riviere, Elaine Luterstein, Vinit Nalawade, Lucas Vitzthum, Reith R Sarkar, Alex K Bryant, John P Einck, Arno J Mundt, James D Murphy and 1 more

Abstract read
PubMed Publisher
In one paragraph

Article in Prostate cancer and prostatic diseases, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 1 pooled it
0.7field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 1 synthesis or guideline pooled it, 14 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Review
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Abhishek Kumar *Department of Radiation Medicine and Applied Sciences, University of California San Diego, La Jolla, CA, USA.
Paul Riviere *Department of Radiation Medicine and Applied Sciences, University of California San Diego, La Jolla, CA, USA.ORCID http://orcid.org/0000-0001-7966-3090
Elaine LutersteinDepartment of Radiation Medicine and Applied Sciences, University of California San Diego, La Jolla, CA, USA.
Vinit NalawadeDepartment of Radiation Medicine and Applied Sciences, University of California San Diego, La Jolla, CA, USA.ORCID http://orcid.org/0000-0002-6594-6740
Lucas VitzthumDepartment of Radiation Medicine and Applied Sciences, University of California San Diego, La Jolla, CA, USA.
Reith R SarkarDepartment of Radiation Medicine and Applied Sciences, University of California San Diego, La Jolla, CA, USA.
Alex K BryantDepartment of Radiation Oncology, University of Michigan, Ann Arbor, MI, USA.
John P EinckDepartment of Radiation Medicine and Applied Sciences, University of California San Diego, La Jolla, CA, USA.
Arno J MundtDepartment of Radiation Medicine and Applied Sciences, University of California San Diego, La Jolla, CA, USA.
James D MurphyDepartment of Radiation Medicine and Applied Sciences, University of California San Diego, La Jolla, CA, USA.
Brent S RoseDepartment of Radiation Medicine and Applied Sciences, University of California San Diego, La Jolla, CA, USA. bsrose@ucsd.edu.ORCID http://orcid.org/0000-0002-3197-9552
University of California San Diego · USUniversity of Michigan · US

Funding

UC San Diego Clinical and Translational Research InstituteTL1TR001443 · NCATS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI DEPP, COLIN A. · 2015 to 2019
$3.4M
NCATS NIH HHS TL1 TR001443
6 · The paper itself

Abstract

backgroundIncreasing evidence indicates an association between statins and reduced prostate cancer-specific mortality (PCSM). However, significant bias may exist in these studies. One particularly challenging bias to assess is the healthy user effect, which may be quantified by screening patterns. We aimed to evaluate the association between statin use, screening, and PCSM in a dataset with detailed longitudinal information.

methodsWe used the Veterans Affairs Informatics and Computing Infrastructure to assemble a cohort of patients diagnosed with prostate cancer (PC) between 2000 and 2015. We collected patient-level demographic, comorbidity, and tumor data. We also assessed markers of preventive care utilization including cholesterol and prostate specific antigen (PSA) screening rates. Patients were considered prediagnosis statin users if they had at least one prescription one or more years prior to PC diagnosis. We evaluated PCSM using hierarchical Fine-Gray regression models and all-cause mortality (ACM) using a cox regression model.

resultsThe final cohort contained 68,432 men including 40,772 (59.6%) prediagnosis statin users and 27,660 (40.4%) nonusers. Prediagnosis statin users had higher screening rates than nonusers for cholesterol (90 vs. 69%, p < 0.001) and PSA (76 vs. 67%, p < 0.001). In the model which excluded screening, prediagnosis statin users had improved PCSM (SHR 0.90, 95% CI 0.84-0.97; p = 0.004) and ACM (HR 0.96, 95% CI 0.93-0.99; p = 0.02). However, after including cholesterol and PSA screening rates, prediagnosis statin users and nonusers showed no differences in PCSM (SHR 0.98, 95% CI 0.91-1.06; p = 0.59) or ACM (HR 1.02, 95% CI 0.98-1.05; p = 0.25).

conclusionWe found that statin users tend to have more screening than nonusers. When we considered screening utilization, we observed no relationship between statin use before a prostate cancer diagnosis and prostate cancer mortality.

Indexed as

AgedCholesterolDrug PrescriptionsFollow-Up StudiesHumansHydroxymethylglutaryl-CoA Reductase InhibitorsKallikreinsMaleMass ScreeningMiddle AgedPatient Acceptance of Health CarePreventive MedicineProstate-Specific AntigenProstatic NeoplasmsUnited StatesUnited States Department of Veterans AffairsCholesterolHydroxymethylglutaryl-CoA Reductase InhibitorsKallikreinsKLK3 protein, humanProstate-Specific Antigen

Identifiers

PMID32029930
OpenAlexW3004770037

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.